Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2024; 30(38): 4249-4253
Published online Oct 14, 2024. doi: 10.3748/wjg.v30.i38.4249
Anti-tumor efficacy of Calculus bovis: Suppressing liver cancer by targeting tumor-associated macrophages
Ishita Kathuria, Bhupesh Singla
Ishita Kathuria, Bhupesh Singla, Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, TN 38103, United States
Author contributions: Kathuria I contributed an outline of the manuscript and wrote the first draft of the manuscript; Singla B provided feedback, edited the text, and proofread the article.
Supported by the National Institutes of Health grants, No. K99HL146954 and No. R00HL146954; and the UTHSC College of Pharmacy Research Seed Grant award, No. 2023.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bhupesh Singla, MSc, PhD, Assistant Professor, Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, 881 Madison Ave, Room 446, Memphis, TN 38103, United States. bsingla@uthsc.edu
Received: July 31, 2024
Revised: September 10, 2024
Accepted: September 18, 2024
Published online: October 14, 2024
Processing time: 59 Days and 17.3 Hours
Abstract

Despite significant advances in our understanding of the molecular pathogenesis of liver cancer and the availability of novel pharmacotherapies, liver cancer remains the fourth leading cause of cancer-related mortality worldwide. Tumor relapse, resistance to current anti-cancer drugs, metastasis, and organ toxicity are the major challenges that prevent considerable improvements in patient survival and quality of life. Calculus bovis (CB), an ancient Chinese medicinal drug, has been used to treat various pathologies, including stroke, convulsion, epilepsy, pain, and cancer. In this editorial, we discuss the research findings recently published by Huang et al on the therapeutic effects of CB in inhibiting the development of liver cancer. Utilizing the comprehensive transcriptomic analyses, in vitro experiments, and in vivo studies, the authors demonstrated that CB treatment inhibits the tumor-promoting M2 phenotype of tumor-associated macrophages via downregulating Wnt pathway. While multiple studies have been performed to explore the molecular mechanisms regulated by CB, this study uniquely shows its role in modulating the M2 phenotype of macrophages present within the tumor microenvironment. This study opens new avenues of future investigations aimed at investigating this drug’s efficacy in various mouse models including the effects of combination therapy, and against drug-resistant tumors.

Keywords: Calculus bovis; Liver cancer; M2-like tumor associated macrophages; Wnt/β-catenin pathway; Tumor environment

Core Tip: Calculus bovis, a traditional animal drug used in China, has been recognized for its therapeutic effects across various organ systems, including the central nervous, cardiovascular, respiratory, and digestive systems. Recent studies have also suggested its anti-tumor potential. While previous studies have explored the mechanisms of action of its active compounds, this study provides novel insights into its anti-tumor potential using a liver cancer xenograft model. M2 macrophages are associated with tumor progression because they promote tumor growth, angiogenesis, and metastasis while inhibiting effective anti-tumor immune responses. This study, for the first time, demonstrates that Calculus bovis modulates the tumor environment by governing M2-tumor-associated macrophages in a Wnt pathway-dependent manner, thereby suppressing tumor growth.